Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy.

Pierfrancesco Franco(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Umberto Ricardi(Azienda Ospedaliero Universitaria San Giovanni Battista), Angela Botticella(Azienda Ospedaliero Universitaria San Giovanni Battista), Alberto De Crescenzo, Corrado Tarella(European Institute of Oncology), Patrizia Ciammella(Azienda Sanitaria Unità Locale di Reggio Emilia), A. Namysł-Kaletka(The Maria Sklodowska-Curie National Research Institute of Oncology), Andrea Riccardo Filippi(University of Turin)

PubMed

June 1, 2011

Cited by 3

Related Papers

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

|The Lancet Oncology|2020|1.1k

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

|Radiotherapy and Oncology|2020|646

An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer

|Clinical Lung Cancer|2014|437

SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease

|Neuro-Oncology|2013|371

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial

|Blood|2007|307